Showing results (351-360 of 388) with videos related to

Sort By:
Pageof 39
Investigational New Drugs|March 21, 2022
Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinomaSteven F Powell, Miroslaw Mazurczak, Elie G Dib, et al.
ESMO Open|May 22, 2025
Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic cancerD Mahalingam, A Saeed, S F Powell, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 2, 2016
Rare genetic variation in UNC13A may modify survival in amyotrophic lateral sclerosisBenjamin Gaastra, Aleksey Shatunov, Sara Pulit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2025
Phase 1 and 2 Clinical Studies of the STING Agonist Ulevostinag With and Without Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors or LymphomasKevin J Harrington, Stephane Champiat, Joshua D Brody, et al.
The Plant Journal : for Cell and Molecular Biology|November 13, 2019
PEATmoss (Physcomitrella Expression Atlas Tool): a unified gene expression atlas for the model plant Physcomitrella patensNoe Fernandez-Pozo, Fabian B Haas, Rabea Meyberg, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 24, 2018
24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung CancerHossein Borghaei, Corey J Langer, Shirish Gadgeel, et al.
The Lancet. Oncology|October 18, 2016
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 studyCorey J Langer, Shirish M Gadgeel, Hossein Borghaei, et al.
Neurobiology of Aging|April 17, 2013
Residual association at C9orf72 suggests an alternative amyotrophic lateral sclerosis-causing hexanucleotide repeatAshley R Jones, Ione Woollacott, Aleksey Shatunov, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 24, 2021
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189D Rodríguez-Abreu, S F Powell, M J Hochmair, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2023
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 StudyMarina C Garassino, Shirish Gadgeel, Giovanna Speranza, et al.
Pageof 39